Ovarian Cancer Update
About LCU CME Meetings Patterns of Care Patient Projects
You are here: Home: Audio Program Guide: OCU 2 | 2008 Audio: OCU 2 | 2008
 
 
  Go to interview with Deborah K Armstrong, MD
Go to interview with David R Spriggs, MD
Go to interview with Robert L Coleman, MD
 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Armstrong, MD Deborah K Armstrong, MD
Associate Professor of Oncology
Associate Professor of Gynecology
and Obstetrics, The Sidney Kimmel
Comprehensive Cancer Center
The Johns Hopkins University
Baltimore, Maryland
  
  Click here to download the entire interview  
Track 1 GOG-0218: Carboplatin/paclitaxel versus carboplatin/paclitaxel/bevacizumab with or without extended bevacizumab for Stage III or IV ovarian epithelial or primary peritoneal cancer
Track 2 Phase II trial of intraperitoneal carboplatin/paclitaxel with bevacizumab
Track 3 Rationale for targeting the vasculature in the treatment of ovarian cancer
Track 4 Incidence of bowel perforations secondary to bevacizumab
Track 5 Clinical indications for the use of bevacizumab
Track 6 Historical perspective on the use of intraperitoneal therapy

Track 7 Clinical trials comparing intravenous to intraperitoneal therapy
Track 8 Selecting patients for intraperitoneal therapy
Track 9 Complications and quality-of-life issues with intraperitoneal therapy
Track 10 Monitoring and treating asymptomatic patients with rising CA125 levels
Track 11 Treatment alternatives for patients whose disease recurs within six months of primary therapy
Track 12 Management of platinum-resistant versus platinum-sensitive disease
Track 13 Consolidation therapy with a taxane
Track 14 Long-term therapy with pegylated liposomal doxorubicin
Track 15 Tolerability of gemcitabine
Track 16 Indications for surgery in recurrent disease
Track 17 Use of CA125 to monitor treatment and detect disease progression
Track 18 Complementary therapies in the treatment of ovarian cancer
Track 19 Management of intractable ascites associated with advanced disease
Track 20 Screening modalities for women with BRCA1 or BRCA2 mutations
Track 21 Prophylactic hysterectomy and bilateral salpingo-oophorectomy for patients at high risk
Track 22 Hyperthermic intraperitoneal therapy in the treatment of ovarian and gastrointestinal tumors
     
Spriggs, MD David R Spriggs, MD
Head, Division of Solid Tumor
Oncology; Winthrop Rockefeller
Chair of Medical Oncology, Memorial
Sloan-Kettering Cancer Center
New York, New York
  
  Click here to download the entire interview  
Track 1 Evolution of a clinical trial combining bevacizumab with intraperitoneal chemotherapy
Track 2 Mechanism(s) of action of bevacizumab in ovarian cancer
Track 3 Response to single-agent bevacizumab in ovarian cancer
Track 4 Anti-ascites effect of bevacizumab
Track 5 Rationale for a clinical trial combining intraperitoneal therapy and bevacizumab
Track 6 Risk of bowel perforation secondary to bevacizumab
Track 7 Indications for bevacizumab in clinical practice

Track 8 Barriers to intraperitoneal therapy in community practice
Track 9 Issues affecting acceptance of intraperitoneal therapy in clinical practice
Track 10 Duration of bevacizumab in GOG-0218
Track 11 Phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel and IP cisplatin with IV bevacizumab as first-line therapy for optimal Stage II or Stage III ovarian, primary peritoneal and fallopian tube cancer
Track 12 Safety data from a Phase II trial with extended bevacizumab
Track 13 First-line treatment for optimally versus suboptimally resected disease
Track 14 Disease progression and selection of therapy
audio
Track 15 Pegylated liposomal doxorubicin versus gemcitabine for progressive disease
Track 16 Efficacy and tolerability of gemcitabine in advanced disease
Track 17 Treatment of Stage IC endometrioid ovarian cancer progressing 15 months after initial therapy
audio
Track 18 European versus US standard approaches to low-stage ovarian cancer
Track 19 Assessing patients for disease progression
audio
     
Coleman, MD Robert L Coleman, MD
Professor and Director of Clinical
Research, Department of Gynecologic
Oncology, The University of Texas
MD Anderson Cancer Center
Houston, Texas
  
  Click here to download the entire interview  
Track 1 Angiogenic mechanisms of sprouting and vasculogenic mimicry
Track 2 Relationship between VEGF and bevacizumab
Track 3 Normalization of tumor vasculature as a proposed mechanism of bevacizumab
Track 4 GOG-0213: Adjuvant carboplatin/paclitaxel with or without bevacizumab and/or secondary cytoreduction surgery for platinum-sensitive recurrent ovarian epithelial cancer, primary peritoneal cavity cancer or fallopian tube cancer
Track 5 Eligibility and randomization of GOG-0213
Track 6 Factors influencing the use of bevacizumab in clinical practice

Track 7 Novel agents being evaluated in ovarian cancer
Track 8 Promising new tyrosine kinase inhibitors with multiple targets
Track 9 CA125 to monitor response to pegylated liposomal doxorubicin or topotecan in recurrent ovarian or primary peritoneal cancer
Track 10 Selection of therapies for patients with progressive disease in clinical practice
Track 11 Investigation of maintenance treatment after primary chemotherapy
Track 12 Role of paclitaxel as maintenance therapy in ovarian cancer
Track 13 Gemcitabine/carboplatin in the treatment of platinum-sensitive disease